DAFNA Capital Management LLC Acquires 27,417 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

DAFNA Capital Management LLC raised its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 5.8% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 498,827 shares of the company's stock after buying an additional 27,417 shares during the period. IDEAYA Biosciences comprises about 3.3% of DAFNA Capital Management LLC's investment portfolio, making the stock its 11th biggest holding. DAFNA Capital Management LLC owned 0.58% of IDEAYA Biosciences worth $12,820,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of the business. R Squared Ltd acquired a new position in IDEAYA Biosciences in the 4th quarter worth $35,000. Daiwa Securities Group Inc. lifted its stake in IDEAYA Biosciences by 44.0% in the 4th quarter. Daiwa Securities Group Inc. now owns 2,792 shares of the company's stock valued at $72,000 after purchasing an additional 853 shares during the last quarter. KBC Group NV raised its stake in shares of IDEAYA Biosciences by 84.6% during the fourth quarter. KBC Group NV now owns 4,197 shares of the company's stock valued at $108,000 after acquiring an additional 1,923 shares during the last quarter. Cibc World Markets Corp bought a new stake in shares of IDEAYA Biosciences in the 4th quarter valued at $203,000. Finally, Mariner LLC lifted its position in shares of IDEAYA Biosciences by 9.8% during the 4th quarter. Mariner LLC now owns 9,775 shares of the company's stock valued at $251,000 after acquiring an additional 869 shares during the period. Institutional investors and hedge funds own 98.29% of the company's stock.

Wall Street Analysts Forecast Growth

IDYA has been the subject of several analyst reports. Stephens reaffirmed an "overweight" rating and issued a $50.00 price objective on shares of IDEAYA Biosciences in a report on Friday, February 14th. Cantor Fitzgerald reissued an "overweight" rating on shares of IDEAYA Biosciences in a research report on Monday, January 13th. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $61.00 price target on shares of IDEAYA Biosciences in a research note on Wednesday, January 15th. Two equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, IDEAYA Biosciences presently has an average rating of "Moderate Buy" and a consensus price target of $53.58.

IDEAYA Biosciences Stock Down 4.5%

IDYA stock traded down $0.83 during trading hours on Tuesday, hitting $17.52. The company's stock had a trading volume of 254,660 shares, compared to its average volume of 988,970. The stock has a 50 day moving average price of $17.72 and a two-hundred day moving average price of $22.51. IDEAYA Biosciences, Inc. has a 12 month low of $13.45 and a 12 month high of $44.42. The company has a market capitalization of $1.53 billion, a PE ratio of -5.31 and a beta of 0.26.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported ($0.82) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same quarter last year, the company earned ($0.53) EPS. Sell-side analysts expect that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.